Transactions will fortify company’s U.S. presence.

WuXi PharmaTech plans to buy AppTec Laboratory Services in a deal valued at $151 million. The acquisition adds biologics capabilities to WuXi PharmaTech’s services. The firm will also gain a significant U.S. operational footprint.

It is expected that the combined business operations of WuXi PharmaTech and AppTec in the U.S. and China will enable WuXi PharmaTech to provide a full-service suite of outsourced chemistry and biology services to global pharmaceutical, biotechnology, and medical device clients.

Previous articleBiodel Plans Manufacturing Facility for Injectable Insulin Product
Next articleOsiris and Genzyme Awarded DoD Contract for Acute Radiation Syndrome Treatment Valued at $224.7M